Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pizzi

Showing results (81-90 of 123) with videos related to

Pageof 13
Sort By:
Journal of Medicinal Chemistry|January 15, 2011
Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidateRomano Di Fabio, Giuseppe Alvaro, Cristiana Griffante, et al.
Farmaco (Societa Chimica Italiana : 1989)|September 19, 2003
Benzoazepine derivative as potent antagonists of the glycine binding site associated to the NMDA receptorRomano Di Fabio, Fabrizio Micheli, Davide Baraldi, et al.
Journal of Medicinal Chemistry|April 25, 2009
Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonistRomano Di Fabio, Cristiana Griffante, Giuseppe Alvaro, et al.
Journal of Medicinal Chemistry|November 9, 2010
Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonistColin P Leslie, Matteo Biagetti, Silvia Bison, et al.
Neurocritical Care|February 26, 2022
Pregabalin for Recurrent Seizures in Critical Illness: A Promising Adjunctive Therapy, Especially for cyclic SeizuresKatharina M Busl, Michael W K Fong, Zachary Newcomer, et al.
Neurology|April 7, 2019
Haptoglobin genotype and aneurysmal subarachnoid hemorrhage: Individual patient data analysisBen Gaastra, Dianxu Ren, Sheila Alexander, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|August 8, 2024
Neurovascular coupling methods in healthy individuals using transcranial doppler ultrasonography: A systematic review and consensus agreementJames D Ball, Eleanor Hills, Afzaa Altaf, et al.
Physical Review Letters|April 11, 2025
Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS DetectorG Aad, E Aakvaag, B Abbott, et al.
Physical Review Letters|January 29, 2025
Simultaneous Unbinned Differential Cross-Section Measurement of Twenty-Four Z+jets Kinematic Observables with the ATLAS DetectorG Aad, E Aakvaag, B Abbott, et al.
Physical Review Letters|April 13, 2024
Study of High-Transverse-Momentum Higgs Boson Production in Association with a Vector Boson in the qqbb Final State with the ATLAS DetectorG Aad, B Abbott, K Abeling, et al.
Pageof 13

Showing results (81-90 of 123) with videos related to

Sort By:
Pageof 13
Journal of Medicinal Chemistry|January 15, 2011
Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidateRomano Di Fabio, Giuseppe Alvaro, Cristiana Griffante, et al.
Farmaco (Societa Chimica Italiana : 1989)|September 19, 2003
Benzoazepine derivative as potent antagonists of the glycine binding site associated to the NMDA receptorRomano Di Fabio, Fabrizio Micheli, Davide Baraldi, et al.
Journal of Medicinal Chemistry|April 25, 2009
Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonistRomano Di Fabio, Cristiana Griffante, Giuseppe Alvaro, et al.
Journal of Medicinal Chemistry|November 9, 2010
Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonistColin P Leslie, Matteo Biagetti, Silvia Bison, et al.
Neurocritical Care|February 26, 2022
Pregabalin for Recurrent Seizures in Critical Illness: A Promising Adjunctive Therapy, Especially for cyclic SeizuresKatharina M Busl, Michael W K Fong, Zachary Newcomer, et al.
Neurology|April 7, 2019
Haptoglobin genotype and aneurysmal subarachnoid hemorrhage: Individual patient data analysisBen Gaastra, Dianxu Ren, Sheila Alexander, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|August 8, 2024
Neurovascular coupling methods in healthy individuals using transcranial doppler ultrasonography: A systematic review and consensus agreementJames D Ball, Eleanor Hills, Afzaa Altaf, et al.
Physical Review Letters|April 11, 2025
Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS DetectorG Aad, E Aakvaag, B Abbott, et al.
Physical Review Letters|January 29, 2025
Simultaneous Unbinned Differential Cross-Section Measurement of Twenty-Four Z+jets Kinematic Observables with the ATLAS DetectorG Aad, E Aakvaag, B Abbott, et al.
Physical Review Letters|April 13, 2024
Study of High-Transverse-Momentum Higgs Boson Production in Association with a Vector Boson in the qqbb Final State with the ATLAS DetectorG Aad, B Abbott, K Abeling, et al.
Pageof 13